Abstract
Escherichia coli Ec36 was recovered from a patient in Portugal after treatment with meropenem and colistin. Besides an IncF plasmid with Tn1441d-blaKPC-3, already reported in clinical strains in this country, E. coli Ec36 co-harbored an IncX4::mcr-1 gene. Results highlight emerging co-resistance to carbapenems and polymyxins after therapy with drugs from both classes.
Keywords:
IncX4::mcr-1, IncF::Tn1441d- blaKPC-3, sequence type, Escherichia coli ST744, Klebsiella pneumoniae, multiresistance, Portugal, bacteria; gene, carbapenem, meropenem, colistin, polymixin, fluconazole, linezolid, co-resistance, antimicrobial resistance, antibacterial, antibiotic.
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Colistin / pharmacology
-
Colistin / therapeutic use
-
Drug Resistance, Bacterial
-
Escherichia coli / classification
-
Escherichia coli / drug effects*
-
Escherichia coli / genetics*
-
Escherichia coli Infections / drug therapy
-
Escherichia coli Infections / epidemiology*
-
Escherichia coli Infections / microbiology*
-
Escherichia coli Proteins / genetics*
-
Genotype
-
Humans
-
Meropenem
-
Microbial Sensitivity Tests
-
Portugal / epidemiology
-
Serogroup
-
Thienamycins / pharmacology
-
Thienamycins / therapeutic use
-
beta-Lactamases / genetics*
Substances
-
Anti-Bacterial Agents
-
Escherichia coli Proteins
-
MCR-1 protein, E coli
-
Thienamycins
-
beta-Lactamases
-
beta-lactamase KPC-3, E coli
-
Meropenem
-
Colistin